Pfizer vaccines to be given on priority basis

100,620 doses of jab in stock

Staff Correspondent

2 June, 2021 12:00 AM printer

The Pfizer-BioNTech coronavirus vaccine will be given based on priority as the recently arrived 100,620 doses of the vaccine can be used to vaccinate around 50,000 people, health ministry sources said.

According to the government's plan, this vaccine will be provided to people of a certain age.

Earlier on Monday, Health Minister Zahid Maleque said they will use Pfizer vaccines to inoculate students as per the procedure.

"There has been a discussion with the prime minister about the Pfizer vaccine. We will follow the chronology; if students become eligible, we will also give them the Pfizer vaccine," he said.

Asked who will get the Pfizer jab, Dr Md. Shamsul Haque, Line Director (MNC & AH) of Directorate General of Health Services (DGHS) told the Daily Sun on Tuesday “We didn’t get any instruction regarding this yet.”

Dr. Md. Robed Amin, the spokesperson of the DGHS, said the national vaccine committee will sit soon and decide on the use of Pfizer vaccine.

A consignment of 100,620 doses of the Pfizer Covid-19 vaccine arrived in Dhaka on Monday night. A flight carrying the vaccines landed at Hazrat Shahjalal International Airport at 11.07 pm.

Pfizer-BioNTech vaccine has been kept at the EPI store, health directorate sources said.

Bangladesh received the Pfizer vaccine via the international vaccine alliance Gavi under its worldwide vaccination initiative Covax.

The Directorate General of Drug Administration (DGDA) has earlier given the emergency use authorization (EUA) for the use of Pfizer vaccine on May 27.

This Pfizer vaccine is suitable for people over 12 years of age. The Pfizer jab has two doses with the 2nd one given 3-4 weeks after the first shot.

The Pfizer-BioNTech should be stored at minus 90-60 degrees Celsius. However, the vaccine will remain stable for five days at a temperature of 2-8 degrees Celsius and two hours at 30 degrees Celsius, according to the DGDA.

According to US CDC, based on evidence from clinical trials in people aged 16 years and older, the Pfizer-BioNTech vaccine was 95 per cent effective at preventing laboratory-confirmed COVID-19 illness in people without evidence of a previous infection. In clinical trials, the Pfizer-BioNTech vaccine was also highly effective at preventing laboratory-confirmed COVID-19 illness in adolescents aged 12–15 years, and the immune response in people aged 12–15 years was at least as strong as the immune response in people aged 16–25 years, it added.